Association between SGLT2 inhibitor therapy and prolonged dementia-free survival in older adults with type 2 diabetes: a retrospective cohort study from Germany
Main finding · DementiaResult — go to the resultHazard ratio 0.80 95 % CI 0.70–0.93Authors' conclusion
SGLT2i therapy was associated with a lower incidence of dementia in older adults with T2DM, particularly in men and the very elderly.
Study context
- Population
- Patients aged ≥60 years with T2D receiving metformin and newly prescribed SGLT2i or DPP-4i (2012–2022), without prior neurodegenerative diagnoses; IQVIA Disease Analyzer database, Germanyafter matching
- Participants
- 38,140 patients
- Exposure
- SGLT2i vs DPP-4i
- Outcome
- Incidence of dementia
- Follow-up
- Five years
Methodological detailspropensity-score matched (1:1), Cox proportional hazards models
- Propensity-score matched (1:1)
- Cox proportional hazards models
Main finding
Dementia
Hazard ratio
0.80
95 % CI 0.70–0.93
P = 0.002
By group
SGLT2ivs DPP-4i
HR 0.80 (95 % CI 0.70–0.93); P = 0.002
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR |
|---|---|
| Dementia, patients >80 years | 0.75 |
| Dementia, males | 0.77 |
Original publication
Association between SGLT2 inhibitor therapy and prolonged dementia-free survival in older adults with type 2 diabetes: a retrospective cohort study from Germany. Diabetes Res Clin Pract. Published 20 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →